![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
PARP: NOVEL THERAPEUTIC TARGET TO TREAT CANCER AND INFLAMMATORY DISEASES
Ritchu Sethi* and Sandeep Jain
ABSTRACT Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes, which show differences in structure, cellular location and functions. However, all these enzymes possess poly (ADP-ribosyl)ation activity. Overactivation of PARP enzymes has been implicated in the pathogenesis of several diseases, including stroke, myocardial infarction, diabetes, shock, neurodegenerative disorder and allergy. Inhibitors of PARP-1 activity in combination with DNA-binding antitumor drugs may constitute a suitable strategy in cancer chemotherapy. In addition, PARP inhibitors may be also useful to restore cellular functions in several pathophysiological states and diseases. This review gives an update of the concerning PARP enzyme and their exploitation as pharmacological targets in several illnesses. Keywords: PARP; PARP inhibitors,cancer, inflammation. [Download Article] [Download Certifiate] |